Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

• Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford University Medical Center
• Dr. Liedtke is a recognized thought leader in CAR-T cell therapy and designing clinical trials in AL Amyloidosis and Multiple Myeloma

LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.  Dr. Liedtke brings decades of experience in hematology/oncology clinical trials, clinical trial design, and thought leadership to Nexcella.

“We need more effective treatments to improve the outcomes for patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma,” said Dr. Liedtke. “Nexcella is the only company developing a CAR-T in Amyloidosis with promising early clinical results.  I look forward to working with the Nexcella team to build on progress made to contribute to bringing NXC-201 to U.S. AL Amyloidosis and multiple myeloma patients.”

"It is a pleasure to welcome Dr. Liedtke to Nexcella as a member of our Scientific Advisory Board," stated Ilya Rachman, MD PhD Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added: “Dr. Liedtke’s deep experience with CAR-Ts across indications and thoughtful approach to bringing better options to patients is truly remarkable.  We are excited to be working with Dr. Liedtke.”

Dr. Liedtke is the Stanford University Medicine Cancer Center Program Lead, Hematology; Co-Director, Stanford Amyloid Center; Medical Director, Stanford Adolescent and Young Adult Program; and Member Leukemia Committee, Southwest Oncology Group. Dr. Liedtke is an award-winning hematologist/oncologist, having received the Translational Research Award, Stanford Department of Medicine; Young Investigator Award, American Society of Clinical Oncology (ASCO); Methods in Clinical Cancer Research Scholar, ASCO/AACR; Fellowship Award, Lymphoma Research Foundation; and Translational Research Award, Doris Duke Foundation.  Dr. Leidtke is a member of the American Society of Hematology, American Society of Clinical Oncology, International Myeloma Society, International Society of Amyloidosis, and the Stanford Cardiovascular Institute.  Dr. Liedtke completed her fellowship at Stanford University Medical Center and Memorial Sloan-Kettering Cancer Center, residency at the Albert Einstein College of Medicine, and received her medical degree from Medizinische Hochschule Hannover.